{"id":"NCT00421174","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","briefTitle":"Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)","officialTitle":"A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Idiopathic Pneumonia Syndrome Following Allogeneic Cell Transplantation (BMTCTN0403)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2010-06","completion":"2013-07","firstPosted":"2007-01-11","resultsPosted":"2016-05-16","lastUpdate":"2021-11-01"},"enrollment":37,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pneumonia","Idiopathic Pneumonia Syndrome"],"interventions":[{"type":"DRUG","name":"Etanercept","otherNames":["EnbrelÂ®"]},{"type":"DRUG","name":"Placebo plus corticosteroid","otherNames":["Methylprednisolone"]}],"arms":[{"label":"Etanercept","type":"EXPERIMENTAL"},{"label":"Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The study is designed as a Phase III, multi-center randomized, double-blind, placebo-controlled trial investigating the use of etanercept for the treatment of acute, non-infectious pulmonary dysfunction (IPS) occurring after allogeneic hematopoietic cell transplantation (HCT).","primaryOutcome":{"measure":"Response Rate","timeFrame":"Day 28","effectByArm":[{"arm":"Etanercept","deltaMin":62.5,"sd":null},{"arm":"Placebo","deltaMin":66.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":["24607553"],"seeAlso":["https://bethematch.org/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":[]}}